We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+8.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
–
Cap. Flow
+$100M
Cap. Flow
% of AUM
100.06%
Top 10 Holdings %
Top 10 Hldgs %
20.66%
Holding
249
New
249
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$2.64M |
| 2 |
Invitation Homes
INVH
|
+$2.51M |
| 3 |
iShares MBS ETF
MBB
|
+$2.48M |
| 4 |
Euronet Worldwide
EEFT
|
+$2.17M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.01M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 40.96% |
| 2 | Technology | 10.32% |
| 3 | Real Estate | 9.94% |
| 4 | Industrials | 7.65% |
| 5 | Financials | 4.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$167B
| $2.67M | 2.66% |
+21,761
| New | +$2.64M |
|
|
2
Invitation Homes
INVH
$17.9B
| $2.5M | 2.49% |
+90,000
| New | +$2.51M |
|
|
3
iShares MBS ETF
MBB
$39.3B
| $2.48M | 2.47% |
+26,000
| New | +$2.48M |
|
|
4
Euronet Worldwide
EEFT
$3.1B
| $2.12M | 2.11% |
+27,855
| New | +$2.17M |
|
|
5
Vertex Pharmaceuticals
VRTX
$123B
| $2.11M | 2.11% |
+4,663
| New | +$2.01M |
|
6
AstraZeneca
AZN
$262B
| $1.95M | 1.95% |
+10,622
| New | +$1.86M |
|
|
PINE
7
Alpine Income Property Trust
PINE
$359M
| $1.88M | 1.88% |
+112,674
| New | +$1.76M |
|
8
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
| $1.78M | 1.77% |
+17,209
| New | +$1.73M |
|
9
iShares Russell 1000 Value ETF
IWD
$81.9B
| $1.77M | 1.76% |
+8,407
| New | +$1.74M |
|
10
Ionis Pharmaceuticals
IONS
$8.99B
| $1.47M | 1.46% |
+18,523
| New | +$1.39M |
|
11
Stereotaxis
STXS
$154M
| $1.38M | 1.38% |
+600,000
| New | +$1.6M |
|
12
Incyte
INCY
$23.4B
| $1.33M | 1.33% |
+13,471
| New | +$1.3M |
|
13
Insmed
INSM
$23.5B
| $1.32M | 1.32% |
+7,588
| New | +$1.38M |
|
14
AMREP Corp
AXR
$136M
| $1.22M | 1.22% |
+65,000
| New | +$1.4M |
|
15
argenx
ARGX
$53.8B
| $1.2M | 1.19% |
+1,425
| New | +$1.22M |
|
16
Axsome Therapeutics
AXSM
$11.8B
| $1.11M | 1.11% |
+6,088
| New | +$850K |
|
17
Neurocrine Biosciences
NBIX
$17.2B
| $1.05M | 1.04% |
+7,383
| New | +$1.07M |
|
18
Roivant Sciences
ROIV
$24.8B
| $978K | 0.97% |
+45,076
| New | +$889K |
|
|
BFS
19
Saul Centers
BFS
$899M
| $946K | 0.94% |
+30,000
| New | +$922K |
|
20
iShares US Real Estate ETF
IYR
$4.83B
| $939K | 0.94% |
+10,000
| New | +$953K |
|
|
INGM
21
Ingram Micro Holding
INGM
$6.75B
| $888K | 0.89% |
+41,629
| New | +$903K |
|
22
Intuitive Surgical
ISRG
$122B
| $850K | 0.85% |
+1,500
| New | +$799K |
|
|
CTO
23
CTO Realty Growth
CTO
$751M
| $828K | 0.83% |
+45,000
| New | +$770K |
|
24
Graphic Packaging
GPK
$3.2B
| $828K | 0.83% |
+55,000
| New | +$904K |
|
|
KDK
25
Kodiak AI
KDK
$827M
| $819K | 0.82% |
+75,000
| New | +$601K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for AlphaCentric Advisors, which disclosed 249 positions worth $100M. Its ten largest holdings account for 21% of the portfolio.
Its largest position is Gilead Sciences: 21,761 shares worth $2.67M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, followed by Technology and Real Estate.
- AlphaCentric Advisors's largest Q4 2025 buy was Gilead Sciences: 21,761 shares worth $2.67M.
- AlphaCentric Advisors's ten largest holdings make up 21% of its $100M portfolio in Q4 2025.
- AlphaCentric Advisors disclosed 249 positions in Q4 2025, its first 13F filing on record.
Based on AlphaCentric Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.